Risk Factors for Carbapenem-resistant Gram-negative Bacteremia in Intensive Care Unit Patients
Overview
Authors
Affiliations
Purpose: Carbapenem-resistant (CR) Gram-negative pathogens have increased substantially. This study was performed to identify the risk factors for development of CR Gram-negative bacteremia (GNB) in intensive care unit (ICU) patients.
Methods: Prospective study; risk factors for development of CR-GNB were investigated using two groups of case patients: the first group consisted of patients who acquired carbapenem susceptible (CS) GNB and the second group included patients with CR-GNB. Both case groups were compared to a shared control group defined as patients without bacteremia, hospitalized in the ICU during the same period.
Results: Eighty-five patients with CR- and 84 patients with CS-GNB were compared to 630 control patients, without bacteremia. Presence of VAP (OR 7.59, 95 % CI 4.54-12.69, p < 0.001) and additional intravascular devices (OR 3.69, 95 % CI 2.20-6.20, p < 0.001) were independently associated with CR-GNB. Presence of VAP (OR 2.93, 95 % CI 1.74-4.93, p < 0.001), presence of additional intravascular devices (OR 2.10, 95 % CI 1.23-3.60, p = 0.007) and SOFA score on ICU admission (OR 1.11, 95 % CI 1.03-1.20, p = 0.006) were independently associated with CS-GNB. The duration of exposure to carbapenems (OR 1.079, 95 % CI 1.022-1.139, p = 0.006) and colistin (OR 1.113, 95 % CI 1.046-1.184, p = 0.001) were independent risk factors for acquisition of CR-GNB. When the source of bacteremia was other than VAP, previous administration of carbapenems was the only factor related with the development of CR-GNB (OR 1.086, 95 % CI 1.003-1.177, p = 0.042).
Conclusions: Among ICU patients, VAP development and the presence of additional intravascular devices were the major risk factors for CR-GNB. In the absence of VAP, prior use of carbapenems was the only factor independently related to carbapenem resistance.
Wang J, Mu M, Zhu J, Yang J, Tao Y, Chen Y Ann Hematol. 2024; 103(10):4021-4031.
PMID: 38958702 PMC: 11512823. DOI: 10.1007/s00277-024-05866-x.
Panda S, Dash A, Chhotray P, Nayak B, Mouli T, Mishra S Int J Crit Illn Inj Sci. 2023; 12(4):217-221.
PMID: 36779211 PMC: 9910118. DOI: 10.4103/ijciis.ijciis_34_22.
Li K, Jiang S, Fu H, Hao Y, Tian S, Zhou F Infect Drug Resist. 2023; 15:7777-7787.
PMID: 36597450 PMC: 9805710. DOI: 10.2147/IDR.S398581.
Lu L, Xu C, Tang Y, Wang L, Cheng Q, Chen X Infect Drug Resist. 2022; 15:2901-2914.
PMID: 35693849 PMC: 9176635. DOI: 10.2147/IDR.S359833.
Bao J, Ma Y, Ding M, Wang C, Du G, Zhou Y J Clin Lab Anal. 2021; 35(9):e23915.
PMID: 34331328 PMC: 8418493. DOI: 10.1002/jcla.23915.